2/23
08:00 am
amrn
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Low
Report
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
2/11
08:00 am
amrn
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Low
Report
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
1/29
07:41 am
amrn
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Amarin (NASDAQ:AMRN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/10
03:22 pm
amrn
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights [Yahoo! Finance]
Medium
Report
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights [Yahoo! Finance]
1/9
07:00 am
amrn
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
Medium
Report
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
1/8
07:00 am
amrn
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
High
Report
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities